Tracer library / [131I]I-omburtamab

[131I]I-omburtamab

Also written as [131I]I-omburtamab
Radionuclide
I-131
Modality
—
Production route
—
Stage
Clinical research
Syntheses indexed
0
Brain metastasesNeuroblastoma (paediatric)Dosimetry and biodistribution studies

What it is

Compound class
Murine monoclonal antibody (anti-B7H3, radioiodinated)
Target / mechanism
B7H3 (CD276) PMID 36371226
Clinical application
CNS malignancies with leptomeningeal metastases, including metastatic neuroblastoma and other B7H3-expressing solid tumors PMID 36371226
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Patterns of relapse in diffuse intrinsic pontine glioma after convection-enhanced delivery of 124I-omburtamab.
    2025 · Neurooncol Adv · Clinical study
  2. Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease.
    2024 · EJNMMI Res · Clinical study
  3. Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease.
    2024 · Res Sq · Clinical study
  4. Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.
    2022 · J Hematol Oncol · Clinical study

Need this precursor?We can point you to suppliers for [131I]I-omburtamab, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 5 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 36371226, 36759197, 38464207, 39083105, 40709014. Stage set/updated at stage 39 from PMID 36371226: 'We conducted a phase I trial of intraventricular 131I-omburtamab using a standard 3 + 3 design.'.